Open-label infliximab therapy in ulcerative colitis: A multicenter survey of results and predictors of response

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1609-1614

  Gonzalez Lama, Yago ^a   Fernandez Blanco, Ignacio ^b   Lopez SanRoman, Antonio ^c   Taxonera, Carlos ^d   Casis, Begoña ^e   Tabernero, Susana ^f   Bermejo, Fernando ^g   Martinez Silva, Francisca ^c   Mendoza, Juan Luis ^d   Martinez Montiel, Pilar ^d   Carneros, Jose Antonio ^g   Sanchez, Fernando ^e   Maté, Jose ^a   Gisbert, Javier P ^a,h  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^h Playa de Mojacar   (Spain)

Author keywords

Anti tumor necrosis factor; Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; SALICYLIC ACID DERIVATIVE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FECES INCONTINENCE; FEMALE; FOLLOW UP; HEMATOCHEZIA; HUMAN; LONGITUDINAL STUDY; MALE; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SEX RATIO; SMOKING HABIT; SPAIN; TREATMENT INDICATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 57049189190     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955:1041-1048.
2. Travis SP: Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004; 20(Suppl 4):88-92.
3. Turner D, Walsh CM, Steinhart AH, Griffiths AM: Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5:103-110.
4. Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260.
5. Shibolet O, Regushevskaya. E, Brezis M, Soares-Weiser K: Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005: CD004277.
6. Durai D, Hawthorne AB: Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005; 22:907-916.
7. Garcia S, Gisbert JP, Gomollon F: Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005; 28:607-614.
8. Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-1610.
9. Siddiqui MA, Scott LJ: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65:2179-2208.
10. Ardizzone S, Bianchi Porro G: Biologic therapy for inflammatory bowel disease. Drugs 2005; 65:2253-2286.
11. van Deventer SJ: Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease -- the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999; 13(Suppi 4): 3-8; discussion 38.
12. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N EngI J Med 1999; 340:1398-1405.
13. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
14. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
15. Rutgeerts P, Van Assche G, Vermeire S: Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006; 23:451-463.
16. D'Haens G: Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005; 128:2161-2164.
17. Lichtenstein GR: Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001; 7:89-93.
18. Gisbert JP, Gonzalez Lama Y, Mate Jimenez J: Infliximab therapy in ulcerative colitis: systematic review and meta-analysis. Aliment Pharmacol Ther 2006. (In press)
19. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
20. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
21. Obrador A, Lopez San Roman A, Munoz P, Fortun J, Gassull MA: [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis]. Gastroenterol Hepatol 2003; 26:29-33.
22. Nielsen OH, Gionchetti P, Ainsworth M, Vainer B, Campieri M, Borregaard N, Kjeldsen L: Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999; 94:2923-2928.
23. Ishiguro Y: Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999; 34:66-74.
24. Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, Couturier D, Chaussade S: Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998; 93:2397-2404.
25. Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K: Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33:616-622.
26. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, Duclos B: Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16:144-150.
27. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-181.
28. Tsukada Y, Nakamura T, Iimura M, Tizuka BE, Hayashi N: Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002; 97:2820-2828.
29. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R: Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997; 40:628-633.
30. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM: Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997; 11:1031-1035.
31. Prantera C, Davoli M, Lorenzetti R, Pallone F, Marcheggiano A, Iannoni C, Mariotti S: Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10:41-45.
32. Russell GH, Katz AJ: Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004; 39:166-170.
33. Kugathasan S, Prajapati D, Kim CP, Saeian K, Emmons J, Knox J, Rivera-Bennett T, Werlin SL, Binion DG: Infliximab outcome in children and adults with ulcerative colitis. Gastroenterology 2002; 120:A615.
34. Fuss IJ: Treatment of ulcerative colitis with infliximab: are we there yet? J Pediatr Gastroenterol Nutr 2004; 38:247-249.
35. Rutgeerts P, Feagan B. Olson A, Johnson DR, Travers S, Present DH, Sands BE, Sandborn WJ, Olson A: A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial. Gastroenterology 2005; 128(Suppl 2):689.
36. Sandborn WJ, Feagan B, Olson A. Johnson DR, Travers S, Present DH, Sands BE, Rutgeerts P: A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial results through week 54. Am J Gastroenterol 2005; 100(Suppl):S313.
37. Sandborn WJ, Rachmilewitz D. Hanauer S. Lichtenstein GR, de Villiers WJ, Olson A, Johanns J. Travers S, Colombel JF: Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 trial. Gastroenterology 2005; 128(Suppl 2):688.
38. Rossetti S, Actis GC, Fadda M, Rizzetto M, Palmo A: The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data. Dig Liver Dis 2004; 36:426-431.
39. Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR: Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97:2577-2584.
40. Eidelwein AP, Cuffari C. Abadom V, Oliva-Hemker M: Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11:213-218.
41. Cooper JM, Patterson D, Thirlby RC: Infliximab for ulcerative colitis: not a cure for severe disease. Gastroenterology 2003; 124(Suppl 1):A818.
42. Lim W, Sparrow MP, Hanauer S: The efficacy of infliximab (INF) in ulcerative colitis (UC) - the University of Chicago's experience. Gastroenterology 2005; 128(Suppl 2):W1035.
43. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L. Targan SR. Podolsky DK: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamin Bowel Dis 2001; 7:83-88.
44. McGinnis JK, Murray KF: Infliximab for ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2004; 39(Suppl 1):S282.
45. Hanauer SB: Immunogenicity of infliximab in Crohn's disease. N Engl J Med 2003; 348:2155-2156; author reply 2155-6.
46. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A: Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123:707-713.
47. Gornet JM, Couve S, Hassani Z, Delchier JC, Marteau P, Cosnes J, Bouhnik Y, Dupas JL, Modigliani R, Taillard F, Lemann M: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18:175-181.